Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
2.120
+0.090 (4.43%)
At close: Jan 27, 2026, 4:00 PM EST
2.132
+0.012 (0.58%)
Pre-market: Jan 28, 2026, 9:11 AM EST
Cassava Sciences Employees
Cassava Sciences had 30 employees as of December 31, 2024. The number of employees increased by 1 or 3.45% compared to the previous year.
Employees
30
Change (1Y)
1
Growth (1Y)
3.45%
Revenue / Employee
n/a
Profits / Employee
-$3,534,367
Market Cap
102.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 30 | 1 | 3.45% |
| Dec 31, 2023 | 29 | 3 | 11.54% |
| Dec 31, 2022 | 26 | 2 | 8.33% |
| Dec 31, 2021 | 24 | 13 | 118.18% |
| Dec 31, 2020 | 11 | 2 | 22.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Inovio Pharmaceuticals | 134 |
| Seer, Inc. | 134 |
| Precision BioSciences | 108 |
| Korro Bio | 104 |
| MindWalk Holdings | 102 |
| Pyxis Oncology | 44 |
| Vivani Medical | 37 |
SAVA News
- 4 weeks ago - HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 5 weeks ago - FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
- 3 months ago - Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 3 months ago - Cassava Sciences Appoints Dawn C. Bir to the Board of Directors - GlobeNewsWire
- 5 months ago - Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewsWire
- 6 months ago - Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - GlobeNewsWire
- 7 months ago - Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting - GlobeNewsWire